Creatine for treating muscle disorders.

BACKGROUND Progressive muscle weakness is a main symptom of most hereditary and acquired muscle diseases. Creatine improves muscle performance in healthy individuals. This is an update of our 2007 Cochrane review that evaluated creatine treatment in muscle disorders. Previous updates were in 2009 and 2011. OBJECTIVES To evaluate the efficacy of creatine compared to placebo for the treatment of muscle weakness in muscle diseases. SEARCH METHODS On 11 September 2012, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL (2012, Issue 9 in The Cochrane Library), MEDLINE (January 1966 to September 2012) and EMBASE (January 1980 to September 2012) for randomised controlled trials (RCTs) of creatine used to treat muscle diseases. SELECTION CRITERIA RCTs or quasi-RCTs of creatine treatment compared to placebo in hereditary muscle diseases or idiopathic inflammatory myopathies. DATA COLLECTION AND ANALYSIS Two authors independently applied the selection criteria, assessed trial quality and extracted data. We obtained missing data from investigators. MAIN RESULTS A total of 14 trials, including 364 randomised participants, met the selection criteria. The risk of bias was low in most studies. Only one trial had a high risk of selection, performance and detection bias. No new studies were identified at this update.Meta-analysis of six trials in muscular dystrophies including 192 participants revealed a significant increase in muscle strength in the creatine group compared to placebo, with a mean difference of 8.47%; (95% confidence intervals (CI) 3.55 to 13.38). Pooled data of four trials including 115 participants showed that a significantly higher number of participants felt better during creatine treatment compared to placebo with a risk ratio of 4.51 (95% CI 2.33 to 8.74). One trial in 37 participants with idiopathic inflammatory myopathies also showed a significant improvement in functional performance. No trial reported any clinically relevant adverse event.In metabolic myopathies, meta-analyses of three cross-over trials including 33 participants revealed no significant difference in muscle strength. One trial reported a significant deterioration of activities of daily living (mean difference 0.54 on a 1 to 10 scale; 95% CI 0.14 to 0.93) and an increase in muscle pain during high-dose creatine treatment in McArdle disease. AUTHORS' CONCLUSIONS High quality evidence from RCTs shows that short- and medium-term creatine treatment increases muscle strength in muscular dystrophies. There is also evidence that creatine improves functional performance in muscular dystrophy and idiopathic inflammatory myopathy. Creatine is well tolerated in these people. High quality but limited evidence from RCTs does not show significant improvement in muscle strength in metabolic myopathies. High-dose creatine treatment impaired activities of daily living and increased muscle pain in McArdle disease.

[1]  U. Sharma,et al.  Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. , 2010, Magnetic resonance imaging.

[2]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[3]  D. Theisen,et al.  Effects of resistance exercise with and without creatine supplementation on gene expression and cell signaling in human skeletal muscle. , 2008, Journal of applied physiology.

[4]  A. Manzur,et al.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2008, The Cochrane database of systematic reviews.

[5]  Jimmy D Bell,et al.  Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. , 2007, Arthritis and rheumatism.

[6]  M. Beal,et al.  Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders , 2007, Muscle & nerve.

[7]  A. Shao,et al.  Risk assessment for creatine monohydrate. , 2006, Regulatory toxicology and pharmacology : RTP.

[8]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[9]  M. Francaux,et al.  Effect of oral creatine supplementation on urinary methylamine, formaldehyde, and formate. , 2005, Medicine and science in sports and exercise.

[10]  K. Chad,et al.  Creatine monohydrate and resistance training increase bone mineral content and density in older men. , 2005, The journal of nutrition, health & aging.

[11]  A. Pestronk,et al.  CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy , 2005, Annals of neurology.

[12]  L. H. van den Berg,et al.  Few adverse effects of long-term creatine supplementation in a placebo-controlled trial. , 2005, International journal of sports medicine.

[13]  T. Klockgether,et al.  Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo‐controlled, double‐blind 31P‐MRS crossover study , 2005, European journal of neurology.

[14]  T. Conrad,et al.  A clinical trial of creatine in ALS , 2004, Neurology.

[15]  J. Farthing,et al.  Effect of creatine ingestion after exercise on muscle thickness in males and females. , 2004, Medicine and science in sports and exercise.

[16]  N. Hattori,et al.  [A clinical trial of creatine monohydrate in muscular dystrophy patients]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[17]  M. Tarnopolsky,et al.  Resistance training exercise and creatine in patients with Charcot–Marie–Tooth disease , 2004, Muscle & nerve.

[18]  Robert H. Brown,et al.  Prophylactic Creatine Administration Mediates Neuroprotection in Cerebral Ischemia in Mice , 2004, The Journal of Neuroscience.

[19]  M. Tarnopolsky,et al.  Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy , 2004, Neurology.

[20]  M. Rose,et al.  Drug treatment for facioscapulohumeral muscular dystrophy. , 2004, The Cochrane database of systematic reviews.

[21]  M. Beal,et al.  Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase , 2004, Neurobiology of Disease.

[22]  M. Tarnopolsky,et al.  Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome b mutation , 2004, Muscle & nerve.

[23]  P. Clarkson,et al.  Effects of repeated creatine supplementation on muscle, plasma, and urine creatine levels. , 2004 .

[24]  M. Tarnopolsky,et al.  Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1 , 2004, Muscle & nerve.

[25]  M. Tarnopolsky,et al.  Effect of creatine and weight training on muscle creatine and performance in vegetarians. , 2003, Medicine and science in sports and exercise.

[26]  S. Swinnen,et al.  Creatine supplementation in Huntington’s disease , 2003, Neurology.

[27]  S. Hersch,et al.  Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice , 2003, Journal of neurochemistry.

[28]  F. Goubel,et al.  Beneficial effects of creatine supplementation in dystrophic patients , 2003, Muscle & nerve.

[29]  J. Veldink,et al.  A randomized sequential trial of creatine in amyotrophic lateral sclerosis , 2003, Annals of neurology.

[30]  C. Wessig,et al.  Creatine monohydrate in DM2/PROMM , 2003, Neurology.

[31]  C. Rasmussen,et al.  Long-term creatine supplementation does not significantly affect clinical markers of health in athletes , 2003, Molecular and Cellular Biochemistry.

[32]  C. Rasmussen,et al.  Creatine supplementation during college football training does not increase the incidence of cramping or injury , 2003, Molecular and Cellular Biochemistry.

[33]  A. Persky,et al.  Single‐ and Multiple‐Dose Pharmacokinetics of Oral Creatine , 2003, Journal of clinical pharmacology.

[34]  H. Hautmann,et al.  Creatine monohydrate in myotonic dystrophy , 2002, Journal of Neurology.

[35]  M. Tarnopolsky,et al.  Dietary supplementation with creatine monohydrate prevents corticosteroid-induced attenuation of growth in young rats. , 2002, Canadian journal of physiology and pharmacology.

[36]  E. Moser,et al.  Effects of Oral Creatine Supplementation in a Patient with MELAS Phenotype and Associated Nephropathy , 2002, Neuropediatrics.

[37]  U. Ruegg,et al.  Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice , 2002, Neuromuscular Disorders.

[38]  K. Chad,et al.  Creatine supplementation combined with resistance training in older men. , 2001, Medicine and science in sports and exercise.

[39]  G. Mora,et al.  Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results , 2001, Journal of the Neurological Sciences.

[40]  K. Yarasheski,et al.  Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. , 2001, Journal of applied physiology.

[41]  O. Andreassen,et al.  Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.

[42]  M. Tarnopolsky,et al.  Creatine transporter and mitochondrial creatine kinase protein content in myopathies , 2001, Muscle & nerve.

[43]  L. Wilkins,et al.  Activate your online subscription , 2001, Neurology.

[44]  A. Straube,et al.  A placebo-controlled crossover trial of creatine in mitochondrial diseases , 2000, Neurology.

[45]  M. Tarnopolsky,et al.  Creatine monohydrate supplementation enhances high-intensity exercise performance in males and females. , 2000, International journal of sport nutrition and exercise metabolism.

[46]  M. Mattson,et al.  Dietary supplement creatine protects against traumatic brain injury , 2000, Annals of neurology.

[47]  N. Olsen,et al.  Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy studies. , 2000, Arthritis and rheumatism.

[48]  M. Francaux,et al.  Adverse Effects of Creatine Supplementation , 2000, Sports medicine.

[49]  M. Wyss,et al.  Creatine and creatinine metabolism. , 2000, Physiological reviews.

[50]  M. Tegenthoff,et al.  Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. , 2000, Archives of neurology.

[51]  Ole A. Andreassen,et al.  Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.

[52]  Hanns Lochmüller,et al.  Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study , 2000, Neurology.

[53]  G J Brewer,et al.  Protective Effect of the Energy Precursor Creatine Against Toxicity of Glutamate and β‐Amyloid in Rat Hippocampal Neurons , 2000, Journal of neurochemistry.

[54]  M. Beal,et al.  Neuroprotective effects of creatine administration against NMDA and malonate toxicity , 2000, Brain Research.

[55]  S. Felber,et al.  Oral creatine supplementation in Duchenne muscular dystrophy: A clinical and 31 P magnetic resonance spectroscopy study , 2000, Neurological research.

[56]  M. Tarnopolsky,et al.  Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. , 2000, Medicine and science in sports and exercise.

[57]  R. Kreis,et al.  Creatine supplementation--part I: performance, clinical chemistry, and muscle volume. , 1999, Medicine and science in sports and exercise.

[58]  F. Hanefeld,et al.  Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies , 1999, Muscle & nerve.

[59]  M. Tarnopolsky,et al.  Direct measurement of high‐energy phosphate compounds in patients with neuromuscular disease , 1999, Muscle & nerve.

[60]  P. Dechent,et al.  Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[61]  M. Francaux,et al.  Long-term oral creatine supplementation does not impair renal function in healthy athletes. , 1999, Medicine and science in sports and exercise.

[62]  Ole A. Andreassen,et al.  Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.

[63]  M. Tarnopolsky,et al.  Creatine monohydrate increases strength in patients with neuromuscular disease , 1999, Neurology.

[64]  U. Rüegg,et al.  Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells , 1998, FEBS letters.

[65]  M. Tarnopolsky,et al.  Oral Creatine Supplementation and Athletic Performance: A Critical Review , 1998, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[66]  M. Wyss,et al.  The therapeutic potential of oral creatine supplementation in muscle disease. , 1998, Medical hypotheses.

[67]  C. Maganaris,et al.  Creatine supplementation enhances maximum voluntary isometric force and endurance capacity in resistance trained men. , 1998, Acta physiologica Scandinavica.

[68]  M. Beal,et al.  Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity , 1998, Experimental Neurology.

[69]  Bruce R. Rosen,et al.  Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease , 1998, The Journal of Neuroscience.

[70]  M. Tarnopolsky,et al.  A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies , 1997, Muscle & nerve.

[71]  E. Romanus,et al.  A functional index in myositis. , 1996, The Journal of rheumatology.

[72]  G Cederblad,et al.  Muscle creatine loading in men. , 1996, Journal of applied physiology.

[73]  D. Constantin-Teodosiu,et al.  Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. , 1996, The American journal of physiology.

[74]  L. Hagenfeldt,et al.  Creatine treatment in MELAS. , 1994, Muscle & nerve.

[75]  J. Boen,et al.  Cloning and sequencing of rat kidney L-arginine:glycine amidinotransferase. Studies on the mechanism of regulation by growth hormone and creatine. , 1994, The Journal of biological chemistry.

[76]  C. Partain,et al.  Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. , 1994, Arthritis and rheumatism.

[77]  E Hultman,et al.  Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. , 1993, Clinical science.

[78]  M. Dalakas,et al.  Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin , 1993, Neurology.

[79]  M. Kilimann,et al.  A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. , 1993, The Journal of biological chemistry.

[80]  M. Wyss,et al.  Mitochondrial creatine kinase: a key enzyme of aerobic energy metabolism. , 1992, Biochimica et biophysica acta.

[81]  E Hultman,et al.  Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. , 1992, Clinical science.

[82]  P. Matthews,et al.  In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondria1 disease , 1991, Neurology.

[83]  P. Matthews,et al.  Phosphorus magnetic resonance spectroscopy of brain in mitochondrial cytopathies , 1990, Annals of neurology.

[84]  V. Dubowitz,et al.  Quantitation of muscle function in children: A prospective study in duchenne muscular dystrophy , 1982, Muscle & nerve.

[85]  G. Lancia,et al.  PHOSPHOCREATININE IN MYOTONIC DYSTROPHY (STEINERT'S DISEASE) , 1979, The Lancet.

[86]  B. Gualano,et al.  Exploring the therapeutic role of creatine supplementation , 2009, Amino Acids.

[87]  M. Tarnopolsky,et al.  Global and targeted gene expression and protein content in skeletal muscle of young men following short-term creatine monohydrate supplementation. , 2008, Physiological genomics.

[88]  Gianni Parise,et al.  Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.

[89]  C. Pieper,et al.  Competing risk of household expansion or institutionalization in late life. , 2003, The journals of gerontology. Series B, Psychological sciences and social sciences.

[90]  F. Hanefeld,et al.  Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. , 2003, Pediatric neurology.

[91]  J. Malin,et al.  Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. , 2002, Archives of neurology.

[92]  J. Stout,et al.  Effects of resistance exercise and creatine supplementation on myasthenia gravis: a case study. , 2001, Medicine and science in sports and exercise.

[93]  W. Kraemer,et al.  American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. , 2000, Medicine and science in sports and exercise.

[94]  R. Price,et al.  Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. , 1995, Arthritis and rheumatism.

[95]  M. Wyss,et al.  Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. , 1992, The Biochemical journal.

[96]  J. Jourdain,et al.  [Dermatomyositis with cardiac involvment and trial treatment with phosphocreatine]. , 1972, Bulletin de la Societe francaise de dermatologie et de syphiligraphie.

[97]  M. Weber,et al.  [Trial therapy of acute polymyositis with phosphocreatine]. , 1967, Bulletin de la Societe francaise de dermatologie et de syphiligraphie.